Processa Pharmaceuticals
PCSA
22 hedge funds and large institutions have $853K invested in Processa Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
29% more funds holding
Funds holding: 17 → 22 (+5)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
33% less capital invested
Capital invested by funds: $1.28M → $853K (-$424K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$591K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$50.3K |
| 3 |
Millennium Management
New York
|
+$40.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.1K |
| 5 |
Renaissance Technologies
New York
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$334K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$78K |
| 3 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$28.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$15 | – | – |
|
PCSA Hedge Fund Activity: Q1 2023 in Review
22 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2023, worth a combined $853K — down 33% from $1.28M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PCSA positions and 3 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $591K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $334K sold.
- 22 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2023, up from 17 in Q4 2022.
- Funds reported $853K of Processa Pharmaceuticals stock for Q1 2023, down 33% quarter-over-quarter.
- 8 funds opened new Processa Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of +5 holders.
- The largest Processa Pharmaceuticals buyer in Q1 2023 was Walleye Capital, an estimated $591K added.
- The largest Processa Pharmaceuticals seller in Q1 2023 was AIGH Capital Management, an estimated $334K sold.
Based on aggregated 13F filings for Q1 2023.